OR WAIT 15 SECS
May 16, 2016.
The Intellectual Property & Science business of Thomson Reuters announced the nominees for the Allicense 2016 Breakthrough Awards, honoring the leading deals of 2015 in Biopharmaceutical Licensing and in Mergers and Acquisitions (M&A).
The awards-to be determined by public vote-will be presented on Wednesday, June 8 at Allicense in San Francisco, CA.
This year’s nominees include five contenders in each of the two categories. Members of the biopharmaceutical community are invited to vote for the top breakthrough deals in each category until 3:45 PM on Wednesday, June 8.
The nominees are:
Licensee & Licenser
Vertex Pharmaceuticals and CRISPR Therapeutics
CRISPR-Cas9 gene editing technology to discover and develop new treatment for genetic diseases
Gilead Sciences and Galapagos
Galapagos' filgotinib targeting rheumatoid arthritis and inflammatory disease
Pfizer and Heptares Therapeutics
Develop novel drugs targeting GPCR against therapeutic indications
AstraZeneca/Medlmmune and Innate Pharma
IPH2201, an anti-NKG2A humanized IgG4 antibody in immuno-oncology
Sanofi/Genzyme and Voyager Therapeutics
Adeno-associated viral (AAV) gene therapies for severe CNS disorders
MERGERS & ACQUISITIONS